BrightGene Bio-Medical Technology Co Ltd
SSE:688166

Watchlist Manager
BrightGene Bio-Medical Technology Co Ltd Logo
BrightGene Bio-Medical Technology Co Ltd
SSE:688166
Watchlist
Price: 29.55 CNY -0.03%
Market Cap: 12.5B CNY
Have any thoughts about
BrightGene Bio-Medical Technology Co Ltd?
Write Note

BrightGene Bio-Medical Technology Co Ltd
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

BrightGene Bio-Medical Technology Co Ltd
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
BrightGene Bio-Medical Technology Co Ltd
SSE:688166
Other Current Liabilities
ÂĄ50.2m
CAGR 3-Years
13%
CAGR 5-Years
2%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Current Liabilities
ÂĄ530.5m
CAGR 3-Years
-8%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Current Liabilities
ÂĄ299.9m
CAGR 3-Years
-28%
CAGR 5-Years
-13%
CAGR 10-Years
10%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Current Liabilities
ÂĄ3B
CAGR 3-Years
13%
CAGR 5-Years
20%
CAGR 10-Years
22%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Current Liabilities
ÂĄ3.6B
CAGR 3-Years
-3%
CAGR 5-Years
2%
CAGR 10-Years
15%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Current Liabilities
ÂĄ101.9m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

BrightGene Bio-Medical Technology Co Ltd
Glance View

Market Cap
12.5B CNY
Industry
Pharmaceuticals

BrightGene Bio-Medical Technology Co., Ltd. emerges as a compelling player in the pharmaceutical landscape, weaving innovation with strategic execution. Specializing in the research, development, and manufacturing of high-quality generic drugs and pharmaceutical intermediates, the company finds its niche at the intersection of science and commerce. Founded with a vision to leverage cutting-edge technologies for developing advanced therapeutic solutions, BrightGene has carved a significant space in both domestic and international markets. Its state-of-the-art facilities reflect a commitment to rigorous quality standards and continual improvement, aligning with its mission to deliver cost-effective healthcare solutions. At the heart of BrightGene's business model is its robust pipeline of generic pharmaceutical products, which it advances from concept to commercialization. The company monetizes its innovations by licensing and supplying active pharmaceutical ingredients (APIs) and finished dosage forms to global partners, including major pharmaceutical companies. This collaborative approach ensures a steady flow of revenue through licensing agreements and joint ventures, positioning BrightGene as not just a manufacturer, but a valued partner in the quest for affordable healthcare. By continuously expanding its product portfolio and refining manufacturing processes, BrightGene sustains its growth trajectory, capitalizing on a market hungry for cost-efficient, high-quality generic medications.

Intrinsic Value
33.52 CNY
Undervaluation 12%
Intrinsic Value
Price

See Also

What is BrightGene Bio-Medical Technology Co Ltd's Other Current Liabilities?
Other Current Liabilities
50.2m CNY

Based on the financial report for Dec 31, 2023, BrightGene Bio-Medical Technology Co Ltd's Other Current Liabilities amounts to 50.2m CNY.

What is BrightGene Bio-Medical Technology Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
2%

Over the last year, the Other Current Liabilities growth was 5%. The average annual Other Current Liabilities growth rates for BrightGene Bio-Medical Technology Co Ltd have been 13% over the past three years , 2% over the past five years .

Back to Top